Metabolic As its name indicates, glyceraldehyde 3-phosphate dehydrogenase (GAPDH) catalyses the conversion of
glyceraldehyde 3-phosphate to D-
glycerate 1,3-bisphosphate. This is the 6th step in the glycolytic breakdown of glucose, an important pathway of energy and carbon molecule supply which takes place in the
cytosol of eukaryotic cells. The conversion occurs in two coupled steps. The first is favourable and allows the second unfavourable step to occur.
Adhesion One of the GAPDH
moonlighting functions is its role in adhesion and binding to other partners. Bacterial GAPDH from
Mycoplasma and
Streptococcus and fungal GAPDH from
Paracoccidioides brasiliensis are known to bind with the human extracellular matrix component and act in adhesion. GAPDH is found to be surface bound contributing in adhesion and also in competitive exclusion of harmful pathogens. GAPDH from
Candida albicans is found to cell-wall associated and binds to
Fibronectin and
Laminin. GAPDH from
probiotics species are known to bind human colonic
mucin and ECM, resulting in enhanced colonization of probiotics in the human gut. Patel D. et al., showed that
Lactobacillus acidophilus GAPDH binds with mucin, acting in adhesion.
Transcription and apoptosis GAPDH can itself activate
transcription. The
OCA-S transcriptional coactivator complex contains GAPDH and
lactate dehydrogenase, two proteins previously only thought to be involved in
metabolism. GAPDH moves between the
cytosol and the
nucleus and may thus link the metabolic state to gene transcription. In 2005, Hara et al. showed that GAPDH initiates
apoptosis. This is not a third function, but can be seen as an activity mediated by GAPDH binding to
DNA like in transcription activation, discussed above. The study demonstrated that GAPDH is
S-nitrosylated by NO in response to cell stress, which causes it to bind to the protein
SIAH1, a
ubiquitin ligase. The complex moves into the nucleus where Siah1 targets nuclear proteins for
degradation, thus initiating controlled cell shutdown. In subsequent study the group demonstrated that
deprenyl, which has been used clinically to treat
Parkinson's disease, strongly reduces the apoptotic action of GAPDH by preventing its S-nitrosylation and might thus be used as a drug.
Metabolic switch GAPDH acts as a reversible metabolic switch under oxidative stress. When cells are exposed to
oxidants, they need excessive amounts of the antioxidant cofactor
NADPH. In the cytosol, NADPH is reduced from NADP+ by several enzymes, three of them catalyze the first steps of the
pentose phosphate pathway. Oxidant-treatments cause an inactivation of GAPDH. This inactivation re-routes temporally the metabolic flux from glycolysis to the pentose phosphate pathway, allowing the cell to generate more NADPH. Under stress conditions, NADPH is needed by some antioxidant-systems including
glutaredoxin and
thioredoxin as well as being essential for the recycling of
gluthathione.
ER-to-Golgi transport GAPDH also appears to be involved in the
vesicle transport from the
endoplasmic reticulum (ER) to the
Golgi apparatus which is part of shipping route for secreted proteins. It was found that GAPDH is recruited by
rab2 to the
vesicular-tubular clusters of the ER where it helps to form
COP 1 vesicles. GAPDH is activated via
tyrosine phosphorylation by
Src.
Additional functions GAPDH, like many other enzymes, has multiple functions. In addition to catalysing the 6th step of
glycolysis, recent evidence implicates GAPDH in other cellular processes. GAPDH has been described to exhibit higher order multifunctionality in the context of maintaining cellular iron homeostasis, specifically as a
chaperone protein for labile heme within cells. This came as a surprise to researchers but it makes evolutionary sense to re-use and adapt existing proteins instead of evolving a novel protein from scratch. == Use as loading control ==